Clinical Trials | March 11, 2026
Roche reports Phase III persevERA breast cancer trial results
Giredestrant shows promise despite missing primary goal
Giredestrant shows promise despite missing primary goal
The licensed intellectual property covers methods and designs for CAR constructs engineered to function in myeloid cell populations
A next-generation, cell-based immunotherapy, CAR-T therapy engineers a patient’s own immune cells to detect and destroy cancer
SYNT-101 is a once-daily oral pill engineered to redirect nutrient absorption beyond the small intestine’s duodenum
Fenebrutinib has the potential to become the first and only high-efficacy oral, brain-penetrant treatment for both RMS and PPMS, showing a profound benefit on relapsing and progressive disease biology
The new solution combines Watchmaker Genomics’ high-performance NGS chemistry with Volta’s digital fluidics platform
CagriSema produced a 23% weight loss at 84 weeks, versus 25.5% for tirzepatide
The program offers selected participants advanced access to Promise Bio’s broad-epiproteomic platform
One of India’s top integrated contract research, development, and manufacturing organizations (CRDMOs) is on a hiring spree
40+ most innovative startups with disruptive contributions across MedTech, Medical Devices, BioPharma, Cell and Gene Therapy, AI and ML, Nutraceuticals, and Biomarkers exhibited their cutting-edge solutions
Subscribe To Our Newsletter & Stay Updated
